Skip to main content
. 2020 Jun 29;48(14):7801–7817. doi: 10.1093/nar/gkaa536

Figure 2.

Figure 2.

LEDGIN treatment retargets integration away from active genes. Integration sites retrieved in each condition in SupT1 (A) and Jurkat (B) cells were divided in four genomic categories and plotted as relative proportions: silent genes (SG), intergenic regions (IR), regulatory elements containing enhancers and promoters (RE) and active genes (AG).